How CJC-1295 Stimulates Growth Hormone

CJC-1295

2-10x GH increase

A single CJC-1295 injection raised growth hormone levels 2- to 10-fold for six or more days in healthy adults.

Teichman et al., J Clin Endocrinol Metab, 2006

Teichman et al., J Clin Endocrinol Metab, 2006

View as image

Growth hormone does not flow from the pituitary at a steady rate. It pulses, peaking during deep sleep, exercise, and fasting, then dropping back to near-zero between bursts. The signal that triggers each pulse starts with a 44-amino-acid peptide called growth hormone-releasing hormone (GHRH), which survives in the bloodstream for about 7 minutes before enzymes chew it apart.^[1] CJC-1295, the focus of this article, is a synthetic GHRH analog engineered to resist that rapid degradation and keep the GH-releasing signal active for days instead of minutes. For a broader look at CJC-1295's effects on the GH/IGF-1 axis, see our pillar article on CJC-1295 and IGF-1 elevation.

What CJC-1295 Actually Is

CJC-1295 is a 30-amino-acid synthetic analog of the first 29 residues of human GHRH (sometimes called GRF 1-29), plus a lysine residue at position 30 for chemical modification. In 2005, Jetté and colleagues identified CJC-1295 by screening a panel of hGRF(1-29)-albumin bioconjugates for their ability to activate the GRF receptor on anterior pituitary cells in rats.^[1] The compound stood out because it maintained receptor activation for far longer than any unmodified GHRH fragment.

Two versions exist in research and clinical contexts. CJC-1295 with DAC (Drug Affinity Complex) includes a maleimidopropionic acid linker that forms a covalent bond with circulating albumin, extending the half-life to approximately 6-8 days. CJC-1295 without DAC, commonly called Modified GRF (1-29) or Mod GRF 1-29, retains the four amino acid substitutions for DPP-IV resistance but lacks the albumin-binding component, giving it a half-life of roughly 30 minutes. For a detailed comparison, see our article on CJC-1295 with DAC vs without DAC.

Step 1: Surviving the Bloodstream

Native GHRH has a half-life of about 7 minutes in human plasma. The primary culprit is dipeptidyl peptidase-IV (DPP-IV), a serine protease that clips GHRH between positions 2 and 3, rendering it inactive.^[2] This is the fundamental problem CJC-1295 was designed to solve.

Four amino acid substitutions address this vulnerability:

• Position 2: Alanine replaced with D-alanine, blocking DPP-IV's primary cleavage site
• Position 8: Asparagine replaced with glutamine, reducing oxidative degradation
• Position 15: Glycine replaced with alanine, improving metabolic stability
• Position 27: Methionine replaced with leucine, preventing methionine oxidation

These substitutions do not alter the peptide's ability to bind and activate the GHRH receptor. They protect the molecule from enzymatic degradation while preserving its biological function.^[1] The D-alanine substitution at position 2 is the most critical change because DPP-IV cleaves specifically after the second residue of native GHRH. Without this single modification, the peptide would be inactivated within minutes of entering the bloodstream, just like endogenous GHRH.

The Albumin-Binding Layer (DAC)

In the DAC version, a second layer of protection extends the half-life further. The maleimidopropionic acid moiety on lysine-30 reacts with free cysteine-34 on serum albumin, forming a stable covalent thioether bond. Because albumin has a circulating half-life of approximately 19 days, the attached CJC-1295 molecule is protected from renal clearance and enzymatic degradation for days.^[1]

Step 2: Binding the GHRH Receptor

CJC-1295 binds to the same GHRH receptor (GHRH-R) as native GHRH. This receptor sits on the surface of somatotroph cells in the anterior pituitary gland. Somatotrophs make up roughly 50% of the anterior pituitary's hormone-producing cells, and they are the exclusive source of circulating growth hormone.

The GHRH receptor is a G-protein coupled receptor (GPCR) belonging to the secretin receptor family (class B). When CJC-1295 binds, it triggers the same intracellular cascade as native GHRH:^[1]

1. Receptor activation: CJC-1295 binds the extracellular domain of GHRH-R, causing a conformational change
2. G-protein coupling: The receptor activates stimulatory G-alpha-s proteins on the intracellular side
3. Adenylyl cyclase activation: G-alpha-s stimulates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP)
4. PKA activation: Rising cAMP activates protein kinase A (PKA)
5. GH release: PKA phosphorylates multiple targets, opening voltage-gated calcium channels and triggering exocytosis of GH-containing vesicles
6. GH gene transcription: PKA also activates the transcription factor Pit-1, which drives expression of the GH gene for new GH synthesis

This entire cascade is identical to what happens when native GHRH binds the receptor. CJC-1295's advantage is not a stronger signal. It is a longer-lasting one.

The cAMP/PKA pathway is not the only signaling route available at the GHRH receptor. GHRH-R activation also increases intracellular calcium through both L-type voltage-gated calcium channels and intracellular calcium stores. This calcium influx is the immediate trigger for exocytosis of GH-containing secretory granules. The dual signaling through cAMP/PKA (for gene transcription and channel phosphorylation) and calcium (for vesicle fusion) ensures that GHRH receptor activation both releases existing GH stores and replenishes them through new synthesis.

Step 3: The Growth Hormone Response

The most detailed human data on CJC-1295's GH-stimulating effects comes from two landmark clinical studies published in 2006.

The Teichman Trial

Teichman and colleagues conducted a dose-escalation study in 56 healthy adults receiving single subcutaneous injections of CJC-1295 at doses ranging from 30 to 300 mcg/kg.^[3] The results showed dose-dependent increases in mean plasma GH concentrations of 2- to 10-fold, sustained for 6 days or longer. At the lowest dose (30 mcg/kg), GH elevation was modest but still measurable. At the highest dose (300 mcg/kg), mean GH rose approximately 10-fold above baseline and remained elevated for the entire observation period. IGF-1 levels rose 1.5- to 3-fold and remained elevated for 9 to 11 days. In the multiple-dose phase, weekly injections of 60 mcg/kg for 2-4 weeks produced cumulative IGF-1 elevation without evidence of tachyphylaxis (loss of response), suggesting that the pituitary does not become desensitized to repeated CJC-1295 exposure over this timeframe.

The Ionescu Study

Ionescu and Frohman examined whether continuous CJC-1295 stimulation would flatten GH pulsatility into a steady-state release, which would be undesirable because pulsatile GH secretion is necessary for normal physiological signaling.^[4] Their findings were clear: pulsatile GH secretion persisted during CJC-1295 stimulation. The peptide increased both the trough levels and the peak amplitude of GH pulses, but the rhythmic pattern of release remained intact. This preservation of pulsatility distinguishes CJC-1295 from exogenous GH injection, which creates a single supraphysiological spike followed by a long trough.

Why Pulsatility Matters

Growth hormone's biological effects depend on its pattern of release, not just its total quantity. Continuous GH exposure downregulates GH receptors on target tissues, reducing the hormone's effectiveness over time. Pulsatile release, by contrast, allows receptors to resensitize between bursts. This is why exogenous GH injections, which create a single large spike, produce different tissue responses than the natural pulsatile pattern, even at the same total daily GH exposure.

The liver's production of IGF-1 is particularly sensitive to GH pulse patterns. Studies have shown that pulsatile GH delivery drives higher IGF-1 output than continuous delivery at equivalent total doses. This makes pulsatility preservation directly relevant to whether CJC-1295 effectively activates the downstream GH/IGF-1 axis.

This distinction matters because CJC-1295 works upstream of GH release. By activating GHRH receptors, it amplifies the pituitary's own release pattern rather than overriding it. The pituitary still responds to somatostatin (the GH-inhibiting hormone), so the natural braking mechanism remains functional.^[4] For more on how somatostatin regulates growth hormone, see our dedicated article.

Bowers and colleagues demonstrated this principle with a related GH secretagogue, showing that 30-day continuous subcutaneous infusion of GHRP-2 combined with GHRH sustained elevated pulsatile GH secretion in older adults without desensitization.^[5] Women showed a greater GH response than men in that study, a pattern consistent with known sex differences in GH axis sensitivity.

The GH-IGF-1 Axis Downstream

CJC-1295's effects extend beyond GH itself. When GH pulses reach the liver, they stimulate production of insulin-like growth factor 1 (IGF-1), the primary mediator of GH's anabolic effects on tissues. This GH-to-IGF-1 conversion is the central axis that CJC-1295 activates.

Sackmann-Sala and colleagues examined what happens downstream of GH/IGF-1 elevation by measuring serum protein profiles in healthy adults treated with CJC-1295.^[6] They found measurable changes in circulating proteins beyond just GH and IGF-1, indicating that CJC-1295 activation of the GH/IGF-1 axis produces broad systemic metabolic effects. Specific proteins involved in lipid metabolism, immune function, and tissue remodeling were altered, consistent with known GH/IGF-1 biology.

The sustained IGF-1 elevation seen with CJC-1295 (9-11 days from a single injection^[3]) makes the peptide fundamentally different from GHRP-class secretagogues like GHRP-2 or GHRP-6, which produce acute GH spikes lasting hours, not days.

Cross-Talk With the Ghrelin System

The GHRH and ghrelin signaling pathways are not fully independent. Casanueva and colleagues demonstrated that GHRH can act as an agonist at the ghrelin receptor (GHS-R1a) at physiologically relevant concentrations.^[7] This cross-talk means CJC-1295 may produce some of its GH-releasing effects through a secondary pathway, activating ghrelin receptors in addition to GHRH receptors.

This dual-receptor engagement could explain why GHRH analogs and ghrelin-receptor agonists (GHRPs) produce synergistic effects when combined. Shah and colleagues showed that GHRP-2 activates the GH axis through three distinct mechanisms: direct pituitary somatotroph stimulation, amplification of endogenous GHRH release, and functional somatostatin withdrawal.^[8] When a GHRH analog like CJC-1295 is paired with a GHRP, both the GHRH-R and GHS-R1a pathways are simultaneously activated, producing GH responses larger than either agent alone.

Preclinical Validation: The GHRH Knockout Model

Alba and colleagues provided direct evidence that CJC-1295 can restore a completely absent GHRH signal. Using mice genetically engineered to lack GHRH (GHRH knockout mice), they showed that once-daily subcutaneous CJC-1295 normalized pulsatile GH secretion and IGF-1 levels.^[2] These mice, which would otherwise remain growth-hormone deficient, achieved normal GH-axis function with CJC-1295 treatment.

This animal model demonstrated several important points about CJC-1295's mechanism. First, the peptide works directly at the pituitary, since these mice have no hypothalamic GHRH to amplify. Second, DPP-IV resistance alone is sufficient for once-daily dosing, even without the DAC modification. Third, the restored GH secretion is pulsatile rather than continuous, indicating that the somatotroph cells themselves maintain rhythmic release patterns even when stimulated by an exogenous GHRH analog. The GHRH knockout model also confirmed that CJC-1295 normalized IGF-1 levels downstream, validating that the entire GH/IGF-1 axis can be reconstituted through a single receptor target.

What the Evidence Does Not Show

CJC-1295 has been studied primarily in short-term trials with small sample sizes. The Teichman trial enrolled 56 subjects; the Ionescu study was even smaller. Long-term safety data beyond a few weeks of dosing does not exist in published peer-reviewed literature.

The clinical development program for CJC-1295 with DAC was discontinued after a participant death during a phase II trial. The cause was attributed to a cardiac event, though the relationship to CJC-1295 was not conclusively established. No subsequent clinical trials have been conducted with the DAC version.

Most mechanistic data comes from the DAC version (CJC-1295 with DAC). The non-DAC version (Mod GRF 1-29) retains the same receptor-binding properties but has a much shorter half-life, producing acute rather than sustained GH elevation. Whether the short-acting version produces the same magnitude of IGF-1 elevation with repeated dosing has not been established in controlled trials.

The mechanism of action itself (GHRH-R binding, cAMP/PKA activation, GH release) is well-characterized. What remains unknown is how months or years of enhanced GHRH signaling would affect pituitary somatotroph function, downstream IGF-1-mediated tissue effects, and long-term cancer risk. IGF-1 is a growth factor with proliferative effects on multiple tissue types, and sustained elevation could theoretically promote growth of pre-existing neoplasms. This risk has not been studied in the context of CJC-1295 specifically.

For a deeper comparison between CJC-1295 formulations, see CJC-1295: The GHRH Analog Explained and our article on Mod GRF 1-29.

The Bottom Line

CJC-1295 stimulates growth hormone release by binding the same GHRH receptor as native GHRH on pituitary somatotroph cells, triggering the cAMP/PKA signaling cascade that releases stored GH and drives new GH synthesis. Its engineering advantage is duration: four amino acid substitutions block DPP-IV degradation, and the optional DAC modification extends the half-life to 6-8 days via albumin binding. Human trial data shows 2- to 10-fold GH elevation and 1.5- to 3-fold IGF-1 elevation from a single injection, with preserved pulsatile secretion. Long-term safety data remains absent, and clinical development of the DAC version has been discontinued.

Frequently Asked Questions

How does CJC-1295 increase growth hormone?

CJC-1295 binds to GHRH receptors on pituitary somatotroph cells, activating the cAMP/PKA signaling pathway that triggers release of stored growth hormone and stimulates new GH gene transcription. A single subcutaneous injection produced dose-dependent GH increases of 2- to 10-fold lasting 6 or more days in a clinical trial of 56 healthy adults (Teichman et al., 2006).

What is the half-life of CJC-1295?

CJC-1295 with DAC has a half-life of approximately 6-8 days due to covalent albumin binding via its Drug Affinity Complex. CJC-1295 without DAC (Modified GRF 1-29) has a much shorter half-life of roughly 30 minutes, retaining only the DPP-IV-resistant amino acid substitutions without the albumin-binding component.

Does CJC-1295 preserve natural GH pulsatility?

Yes. Ionescu and Frohman (2006) demonstrated that pulsatile GH secretion persists during continuous CJC-1295 stimulation. The peptide increases both trough and peak GH levels while maintaining the natural burst pattern, unlike exogenous GH injection which creates a single supraphysiological spike.

What is the difference between CJC-1295 with DAC and without DAC?

Both versions share the same four amino acid substitutions that resist DPP-IV degradation. CJC-1295 with DAC adds a maleimidopropionic acid linker that covalently binds to serum albumin, extending the half-life from roughly 30 minutes to 6-8 days. The DAC version produces sustained GH elevation; the non-DAC version produces acute pulses.

How long does IGF-1 stay elevated after CJC-1295?

In the Teichman et al. (2006) dose-escalation trial, IGF-1 levels rose 1.5- to 3-fold after a single CJC-1295 injection and remained elevated for 9 to 11 days. Multiple weekly doses produced cumulative IGF-1 elevation without loss of response over the study period.

Can CJC-1295 be combined with GHRP peptides?

GHRH analogs like CJC-1295 and ghrelin-receptor agonists (GHRPs) activate different receptor pathways that converge on GH release. Casanueva et al. (2008) showed GHRH can also activate the ghrelin receptor, and Shah et al. (1999) demonstrated that GHRPs amplify GH release through three distinct mechanisms. Combined use produces synergistic GH responses larger than either agent alone.